How to manage the reproductive issues of PCOS: a 2015 integrated endocrinological and gynecological consensus statement of the Italian Society of Endocrinology

This is a preview of subscription content, access via your institution.

References

  1. 1.

    Zawadski JK, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR (eds) Polycystic ovary syndrome. Blackwell Scientific Publications, Boston, pp 377–384

    Google Scholar 

  2. 2.

    The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47

    Article  Google Scholar 

  3. 3.

    Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF, Task Force on the Phenotype of the Polycystic Ovary Syndrome of The Androgen Excess and PCOS Society (2009) The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 91:456–488

    Article  PubMed  Google Scholar 

  4. 4.

    Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, GRADE Working Group et al (2004) Grading quality of evidence and strength of recommendations. Br Med J 328:1490–1494

    Article  Google Scholar 

  5. 5.

    Swiglo BA, Murad MH, Schunemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM (2008) A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab 93:666–673

    Article  CAS  PubMed  Google Scholar 

  6. 6.

    Apter D, Sibila I (1993) Development of children and adolescence: physiological, pathophysiological, and therapeutic aspects. Curr Opin Obstet Gynecol 5:764–773

    Article  CAS  PubMed  Google Scholar 

  7. 7.

    Fanelli F, Gambineri A, Belluomo I, Repaci A, Di Lallo VD, Di Dalmazi G, Mezzullo M, Prontera O, Cuomo G, Zanotti L et al (2013) Androgen profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in healthy normal-weight ovulatory and anovulatory late adolescent and young women. J Clin Endocrinol Metab 98:3058–3067

    Article  CAS  PubMed  Google Scholar 

  8. 8.

    Fauser BC, Tarlatzis BC, Rebar RW, Legro RS, Balen AH, Lobo R, Carmina E, Chang J, Yildiz BO, Laven JS et al (2012) Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 97:28–38

    Article  PubMed  Google Scholar 

  9. 9.

    Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK (2013) Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 98:4565–4592

    Article  CAS  PubMed  Google Scholar 

  10. 10.

    Bolùmar F, Olsen J, Rabagliato M, Sàez-Lloret I, Bisanti L (2000) Body mass index and delayed conception: a European multicenter study on infertility and subfecundity. Am J Epidemiol 151:1072–1079

    Article  PubMed  Google Scholar 

  11. 11.

    Familiari G, Toscano V, Motta PM (1985) Morphological studies of polycystic mouse ovaries induced by dehydroepiandrosterone. Cell Tissue Res 240:519–528

    Article  CAS  PubMed  Google Scholar 

  12. 12.

    Sen A, Prizant H, Light A, Biswas A, Hayes E, Lee HJ, Barad D, Gleicher N, Hammes SR (2014) Androgens regulate ovarian follicular development by increasing follicle stimulating hormone receptor and microRNA-125b expression. Proc Natl Acad Sci USA 111:3008–3013

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  13. 13.

    Blank SK, McCartney CR, Chhabra S, Helm KD, Eagleson CA, Chang RJ, Marshall JC (2009) Modulation of gonadotropin-releasing hormone pulse generator sensitivity to progesterone inhibition in hyperandrogenic adolescent girls—implications for regulation of pubertal maturation. J Clin Endocrinol Metab 94:2360–2366

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  14. 14.

    Dewailly D, Andersen CY, Balen A, Broekmans F, Dilaver N, Fanchin R, Griesinger G, Kelsey TW, La Marca A, Lambalk C (2014) The physiology and clinical utility of anti-Mullerian hormone in women. Hum Reprod Update 20:370–385

    Article  PubMed  Google Scholar 

  15. 15.

    Diamanti-Kandarakis E, Dunaif A (2012) Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev 33:981–1030

    Article  CAS  PubMed  Google Scholar 

  16. 16.

    Tosi F, Negri C, Perrone F, Dorizzi R, Castello R, Bonora E, Moghetti P (2012) Hyperinsulinemia amplifies GnRH agonist stimulated ovarian steroid secretion in women with polycystic ovary syndrome. J Clin Endocrinol Metab 97:1712–1719

    Article  CAS  PubMed  Google Scholar 

  17. 17.

    Tosi F, Negri C, Brun E, Castello R, Faccini G, Bonora E, Muggeo M, Toscano V, Moghetti P (2011) Insulin enhances ACTH-stimulated androgen and glucocorticoid metabolism in hyperandrogenic women. Eur J Endocrinol 164:197–203

    Article  CAS  PubMed  Google Scholar 

  18. 18.

    Pasquali R, Patton L, Pocognoli P, Cognigni GE, Gambineri A (2007) 17-hydroxyprogesterone responses to gonadotropin-releasing hormone disclose distinct phenotypes of functional ovarian hyperandrogenism and polycystic ovary syndrome. J Clin Endocrinol Metab 92:4208–4217

    Article  CAS  PubMed  Google Scholar 

  19. 19.

    Pastor CL, Griffin-Korf ML, Aloi JA, Evans WS, Marshall JC (1998) Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab 83:582–590

    CAS  PubMed  Google Scholar 

  20. 20.

    O’Connor A, Phelan N, Tun TK, Boran G, Gibney J, Roche HM (2010) High-molecular-weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. J Clin Endocrinol Metab 95:1378–1385

    Article  PubMed  Google Scholar 

  21. 21.

    Maleszka A, Smolinska N, Nitkiewicz A, Kiezun M, Chojnowska K, Dobrzyn K, Szwaczek H, Kaminski T (2014) Adiponectin Expression in the Porcine Ovary during the Oestrous Cycle and Its Effect on Ovarian Steroidogenesis. Int J Endocrinol 2014:957076

    PubMed Central  Article  PubMed  Google Scholar 

  22. 22.

    González F (2012) Inflammation in Polycystic Ovary Syndrome: underpinning of insulin resistance and ovarian dysfunction. Steroids 77:300–305

    PubMed Central  Article  PubMed  Google Scholar 

  23. 23.

    Merhi Z (2014) Advanced glycation end products and their relevance in female reproduction. Hum Reprod 29:135–145

    Article  CAS  PubMed  Google Scholar 

  24. 24.

    Tantalaki E, Piperi C, Livadas S, Kollias A, Adamopoulos C, Koulouri A, Christakou C, Diamanti-Kandarakis E (2014) Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS). Hormones (Athens) 13:65–73

    Google Scholar 

  25. 25.

    Hsueh AJ, Kawamura K, Cheng Y, Fauser BC (2014) Intraovarian control of early folliculogenesis. Endocr Rev 9:er20141020 [Epub ahead of print]

    Google Scholar 

  26. 26.

    Pasquali R, Gambineri A, Cavazza C, Ibarra Gasparini D, Ciampaglia W, Cognigni GE, Pagotto U (2011) Heterogeneity in the responsiveness to long-term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol 164:53–60

    Article  CAS  PubMed  Google Scholar 

  27. 27.

    Domecq JP, Prutsky G, Mullan RJ, Hazem A, Sundaresh V, Elamin MB, Phung OJ, Wang A, Hoeger K, Pasquali R et al (2013) Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis. J Clin Endocrinol Metab 98:4655–4663

    Article  CAS  PubMed  Google Scholar 

  28. 28.

    Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ (1998) Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 13:1502–1505

    Article  CAS  PubMed  Google Scholar 

  29. 29.

    Crosignani PG, Colombo M, Vegetti W, Somigliana E, Gessati A, Ragni G (2003) Overweight and obese anovulatory patients with polycystic ovaries: parallel improvements in anthropometric indices, ovarian physiology and fertility rate induced by diet. Hum Reprod 18:1928–1932

    Article  PubMed  Google Scholar 

  30. 30.

    Farquhar C, Brown J, Marjoribanks J (2012) Laparoscopic drilling by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev 6:CD001122

    PubMed  Google Scholar 

  31. 31.

    Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2008) Consensus on infertility treatment related to polycystic ovary syndrome. Fertil Steril 89:505–522

    Article  Google Scholar 

  32. 32.

    ACOG Committee on Practice Bulletins—Gynecology (2009) ACOG Practice Bulletin No. 108: Polycystic ovary syndrome. Obstet Gynecol 114:936–949

    Article  Google Scholar 

  33. 33.

    Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E (2009) Clomiphene and anti-oestrogens for ovulation induction in PCOS. Cochrane Database Syst Rev 4:CD002249

    PubMed  Google Scholar 

  34. 34.

    Tang T, Lord JM, Norman RJ, Yasmin E, Balen AH (2012) Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligoamenorrhoea and subfertility. Cochrane Database Syst Rev 5:CD003053

    PubMed  Google Scholar 

  35. 35.

    Homburg R, Hendriks ML, König TE, Anderson RA, Balen AH, Brincat M, Child T, Davies M, D’Hooghe T, Martinez A, Rajkhowa M, Rueda-Saenz R, Hompes P, Lambalk CB (2012) Clomifene citrate or low-dose FSH for the first-line treatment of infertile women with anovulation associated with polycystic ovary syndrome: a prospective randomized multinational study. Hum Reprod 27:468–473

    Article  CAS  PubMed  Google Scholar 

  36. 36.

    Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, Christman GM, Huang H, Yan Q, Alvero R, NICHD Reproductive Medicine Network et al (2014) Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 371:119–129

    PubMed Central  Article  PubMed  Google Scholar 

  37. 37.

    Moll E, van der Veen F, van Wely M (2007) The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update 13:527–537

    Article  CAS  PubMed  Google Scholar 

  38. 38.

    Vause TD, Cheung AP, Sierra S, Claman P, Graham J, Guillemin JA, Lapensée L, Steward S, Wong BC (2010) Society of Obstetricians and Gynaecologists of Canada. Int J Gynaecol Obstet 111:95–100

    Article  PubMed  Google Scholar 

  39. 39.

    Moll E, Korevaar JC, Bossuyt PM, van der Veen F (2008) Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome? Hum Reprod 23:1830–1834

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  40. 40.

    Li HW, Lee VC, Lau EY, Yeung WS, Ho PC, Ng EH (2014) Cumulative live-birth rate in women with polycystic ovary syndrome or isolated polycystic ovaries undergoing in vitro fertilisation treatment. J Assist Reprod Genet 31:205–211

    PubMed Central  Article  PubMed  Google Scholar 

  41. 41.

    Palomba S, Falbo A, La Sala GB (2013) Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG 120:267–276

    Article  CAS  PubMed  Google Scholar 

  42. 42.

    Heijnen EMEW, Eijkemans MJC, Hughes EG, Laven JSE, Macklon NS, Fauser BCJM (2006) A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update 12:13–21

    Article  CAS  PubMed  Google Scholar 

  43. 43.

    Leader A; Monofollicular Ovulation Induction Study Group (2006) Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low-dose step-up protocol with weekly increments of 25 international units of follicle-stimulating hormone. Fertil Steril 85:1766–1773

    Article  Google Scholar 

  44. 44.

    van Wely M, Bayram N, van der Veen F (2003) Recombinant FSH in alternative doses or versus urinary gonadotrophins for ovulation induction in subfertility associated with polycystic ovary syndrome: a systematic review based on a Cochrane review. Hum Reprod 18:1143–1149

    Article  CAS  PubMed  Google Scholar 

  45. 45.

    Pundir J, Sunkara SK, El-Toukhy T, Khalaf Y (2012) Meta-analysis of GnRH antagonist Protocols: do they reduce the risk of OHSS in PCOS? Reprod Biomed Online 24:6–22

    Article  CAS  PubMed  Google Scholar 

  46. 46.

    Tso LO, Costello MF, Albuquerque LE, Andriolo RB, Macedo CR (2014) Metformin Treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev 11:CD006105

    PubMed  Google Scholar 

  47. 47.

    Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, Pugeat M, Qiao J, Wijeyaratne CN, Witchel SF, Norman RJ (2012) Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 18:146–170

    Article  CAS  PubMed  Google Scholar 

  48. 48.

    Kiddy DS, Hamilton-Fairley D, Bush A, Short F, Anyaoku V, Reed MJ, Franks S (1992) Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36:105–111

    Article  CAS  Google Scholar 

  49. 49.

    Kuchenbecker WK, Groen H, van Asselt SJ, Bolster JH, Zwerver J, Slart RH, Vd Jagt EJ, Muller Kobold AC, Wolffenbuttel BH, Land JA, Hoek A (2011) In women with polycystic ovary syndrome and obesity, loss of intra-abdominal fat is associated with resumption of ovulation. Hum Reprod 26:2505–2512

    Article  PubMed  Google Scholar 

  50. 50.

    Palomba S, Falbo A, Zullo F, Orio F Jr (2009) Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 30:1–50

    Article  CAS  PubMed  Google Scholar 

  51. 51.

    Carmina E (2013) Oral contraceptives and cardiovascular risk in women with polycystic ovary syndrome. J Endocrinol Invest 36:358–363

    CAS  PubMed  Google Scholar 

  52. 52.

    Lidegaard Ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E (2011) Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001–9. BMJ 343:d6423

    PubMed Central  Article  PubMed  Google Scholar 

  53. 53.

    Lidegaard Ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N (2012) Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 366:2257–2266

    Article  CAS  PubMed  Google Scholar 

  54. 54.

    Randeva HS, Tan BK, Weickert MO, Lois K, Nestler JE, Sattar N, Lehnert H (2012) Cardiometabolic aspects of the polycystic ovary syndrome. Endocr Rev 33:812–841

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  55. 55.

    Vandenheuvel MW, VanBragt AJ, Alnabawy AK, Kaptein MC (2005) Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception 72:168–174

    Article  CAS  Google Scholar 

  56. 56.

    Guastella E, Longo RA, Carmina E (2010) Clinical and endocrine characteristics of the main PCOS phenotypes. Fertil Steril 94:2197–2201

    Article  CAS  PubMed  Google Scholar 

  57. 57.

    Moghetti P, Tosi F, Bonin C, Di Sarra D, Fiers T, Kaufman JM, Giagulli VA, Signori C, Zambotti F, Dall’Alda M, Spiazzi G, Zanolin ME, Bonora E (2013) Divergences in insulin resistance between the different phenotypes of the polycystic ovary syndrome. J Clin Endocrinol Metab 98:E628–E637

    Article  CAS  PubMed  Google Scholar 

  58. 58.

    Lopez LM, Grimes DA, Schulz KF (2014) Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus. Cochrane Database Syst Rev 4:CD006133

    PubMed  Google Scholar 

  59. 59.

    Bird ST, Hartzema AG, Brophy JM, Etminan M, Delaney JA (2013) Risk of venous thromboembolism in women with polycystic ovary syndrome: a population-based matched cohort analysis. CMAJ 185:E115–E120

    PubMed Central  Article  PubMed  Google Scholar 

  60. 60.

    Murthy AS (2010) Obesity and contraception: emerging issues. Semin Reprod Med 28:156–163

    Article  PubMed  Google Scholar 

  61. 61.

    Lenzer J (2011) US panel rules that warnings on two birth control pills be strengthened. BMJ 343:d8104

    Article  PubMed  Google Scholar 

  62. 62.

    Burke AE (2011) The state of hormonal contraception today: benefits and risks of hormonal contraceptives: progestin-only contraceptives. Am J Obstet Gynecol 205(4 Suppl):S14–S17

    Article  CAS  PubMed  Google Scholar 

  63. 63.

    Lidegaard Ø (2014) Hormonal contraception, thrombosis and age. Expert Opin Drug Saf 13:1353–1360

    Article  CAS  PubMed  Google Scholar 

  64. 64.

    De Leo V, la Marca A, Petraglia F (2003) Insulin-lowering agents in the management of polycystic ovary syndrome. Endocr Rev 24:633–667

    Article  PubMed  Google Scholar 

  65. 65.

    Nestler JE (2008) Metformin in the treatment of infertility in polycystic ovarian syndrome: an alternative perspective. Fertil Steril 90:14–16

    PubMed Central  Article  CAS  PubMed  Google Scholar 

  66. 66.

    Moghetti P (2012) For what reasons should metformin be used in the management of polycystic ovary syndrome? J Endocrinol Invest 35:87–89

    CAS  PubMed  Google Scholar 

  67. 67.

    Panidis D, Tziomalos K, Papadakis E, Kandaraki EA, Katsikis I (2013) The guidelines issued by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine regarding the induction of ovulation with metformin in patients with the polycystic ovary syndrome potentially require reconsideration. Hormones (Athens) 12:192–200

    Article  Google Scholar 

  68. 68.

    Conway G, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Franks S, Gambineri A, Kelestimur F, Macut D, Micic D, Pasquali R, Pfeifer M, Pignatelli D, Pugeat M, Yildiz BO, ESE PCOS Special Interest Group (2014) The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol 171:P1–P29

    Article  CAS  PubMed  Google Scholar 

  69. 69.

    Christakou C, Kollias A, Piperi C, Katsikis I, Panidis D, Diamanti-Kandarakis E (2014) The benefit-to-risk ratio of common treatments in PCOS: effect of oral contraceptives versus metformin on atherogenic markers. Hormones (Athens) 13:488–497

    Google Scholar 

  70. 70.

    Glintborg D, Altinok ML, Mumm H, Hermann AP, Ravn P, Andersen M (2014) Body composition is improved during 12 months’ treatment with metformin alone or combined with oral contraceptives compared with treatment with oral contraceptives in polycystic ovary syndrome. J Clin Endocrinol Metab 99:2584–2591

    Article  CAS  PubMed  Google Scholar 

  71. 71.

    Johansson J, Stener-Victorin E (2013) Polycystic ovary syndrome: effect and mechanisms of acupuncture for ovulation induction. Evid Based Complement Alternat Med 2013:762615

    PubMed Central  Article  PubMed  Google Scholar 

  72. 72.

    Raval AD, Hunter T, Stuckey B, Hart RJ (2011) Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev 10:CD008565

    PubMed  Google Scholar 

  73. 73.

    Puurunen J, Piltonen T, Puukka K, Ruokonen A, Savolainen MJ, Bloigu R, Morin-Papunen L, Tapanainen JS (2013) Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 98:4798–4807

    Article  CAS  PubMed  Google Scholar 

  74. 74.

    Gambineri A, Patton L, Vaccina A, Cacciari M, Morselli-Labate AM, Cavazza C, Pagotto U, Pasquali R (2006) Treatment with flutamide, metformin, and their combination added to a hypocaloric diet in overweight-obese women with polycystic ovary syndrome: a randomized, 12-month, placebo-controlled study. J Clin Endocrinol Metab 91:3970–3980

    Article  CAS  PubMed  Google Scholar 

  75. 75.

    Brahm J, Brahm M, Segovia R, Latorre R, Zapata R, Poniachik J, Buckel E, Contreras L (2011) Acute and fulminant hepatitis induced by flutamide: case series report and review of the literature. Ann Hepatol 10:93–98

    PubMed  Google Scholar 

  76. 76.

    Bruni V, Peruzzi E, Dei M, Nannini S, Seravalli V, Sisti G, Fambrini M (2012) Hepatotoxicity with low- and ultralow-dose flutamide: a surveillance study on 203 hyperandrogenic young females. Fertil Steril 98:1047–1052

    Article  CAS  PubMed  Google Scholar 

  77. 77.

    Escobar-Morreale HF (2012) Surgical management of metabolic dysfunction in PCOS. Steroids 77:312–316

    Article  CAS  PubMed  Google Scholar 

  78. 78.

    Falsetti L, Pasinetti E (1995) Effects of long term administration of an oral contraceptive containing ethinyl/estradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 74:56–60

    Article  CAS  PubMed  Google Scholar 

  79. 79.

    Escobar-Morreale H, Asuncion MA, Sancho J (2000) Treatment of hirsutism with ethinyl/estradiol desogestrel contraceptive pills has beneficial effects on lipid profile and improves insulin sensitivity. Fertil Steril 74:816–819

    Article  CAS  PubMed  Google Scholar 

  80. 80.

    Cibula D, Fanta M, Hill M, Sindelka A, Skrha J, Zivny J (2002) Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low androgenic progestin. Hum Reprod 17:76–82

    Article  CAS  PubMed  Google Scholar 

  81. 81.

    Elter K, Imir G, Durmusoglu F (2002) Clinical, endocrine and metabolic effects of metformin added to ethinyl/estradiol-cyproterone acetate in non-obese women with polycystic ovary syndrome: a randomized control study. Hum Reprod 17:1729–1737

    Article  CAS  PubMed  Google Scholar 

  82. 82.

    Cagnacci A, Paoletti AM, Renzi A, Orrù M, Pilloni M, Melis GB, Volpe A (2003) Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel. J Clin Endocrinol Metab 88:3621–3625

    Article  CAS  PubMed  Google Scholar 

  83. 83.

    Morin Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen JS (2003) Metformin versus ethinyl/estradiol-cyproterone acetate in the treatment of non-obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 88:148–156

    Article  CAS  PubMed  Google Scholar 

  84. 84.

    Fruzzetti F, Perini D, Lazzarini V, Parrini D, Gambacciani M, Genazzani AR (2010) Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome. Fertil Steril 94:1793–1798

    Article  CAS  PubMed  Google Scholar 

  85. 85.

    Uras R, Orrù M, Pani F, Marotto MF, Pilloni M, Guerriero S, Etzi R, Zedda P, Sorge R, Lello S, Melis GB, Paoletti AM (2010) Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome. Contraception 82:131–138

    Article  CAS  PubMed  Google Scholar 

  86. 86.

    Cullberg G, Hamberger L, Mattsson LA, Mobacken H, Samsioe G (1985) Effect of low dose desogestrel-ethinyl/estradiol combination on hirsutism, androgens and sex hormone binding globulins in women with polycystic ovary syndrome. Acta Obstet Gynecol Scand 64:195–202

    Article  CAS  PubMed  Google Scholar 

  87. 87.

    Guido M, Romualdi D, Giuliani M, Suriano R, Selvaggi L, Apa R, Lanzone A (2004) Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study. J Clin Endocrinol Metab 89:2817–2823

    Article  CAS  PubMed  Google Scholar 

  88. 88.

    Vribokova J, Cibula D (2005) Combined oral contraceptives in the treatment of polycystic ovary syndrome. Hum Reprod Update 11:277–291

    Article  Google Scholar 

  89. 89.

    Rautio K, Tapanainen JC, Ruokonen A, Morin-Papunen LC (2005) Effects of metformin and ethinyl/estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. Eur J Endocrinol 152:269–275

    Article  CAS  PubMed  Google Scholar 

  90. 90.

    Nader S, Riad Gabriel MG, Saad MF (1997) The effect of desogestrel containing oral contraceptives on glucose tolerance and leptin concentrations in hyperandrogenic women. J Clin Endocrinol Metab 82:3074–3077

    CAS  PubMed  Google Scholar 

  91. 91.

    Morin-Papunen LC, Vauhkonen K, Koivunen RM, Puokonen A, Martikainen HK, Tapanainen JS (2000) Endocrine and metabolic effects of metformin versus ethinyl/estradiol cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 85:3161–3168

    CAS  PubMed  Google Scholar 

  92. 92.

    Palep Singh M, Barth JH, Mook K, Balen AH (2004) An observation study of Yasmin in the management of polycystic ovary syndrome. J Fam Plan Repro Health Care 30:163–165

    Article  Google Scholar 

  93. 93.

    Cibula D, Hill M, Fanta M, Sindelka G, Zivny J (2001) Does obesity diminish the positive effect of oral contraceptive treatment on hyperandrogenism in women with polycystic ovary syndrome? Hum Reprod 16:940–944

    Article  CAS  PubMed  Google Scholar 

  94. 94.

    Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ (2007) Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 92:456–461

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors have no conflict of interest to disclose. No funding supported the preparation of this paper.

Ethical approval

(Research involving Human Participants and/or Animals): not applicable (review of available literature and development of recommendations).

Informed consent

Not applicable (review of available literature and development of recommendations).

Author information

Affiliations

Authors

Corresponding author

Correspondence to P. Moghetti.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Moghetti, P., Carmina, E., De Leo, V. et al. How to manage the reproductive issues of PCOS: a 2015 integrated endocrinological and gynecological consensus statement of the Italian Society of Endocrinology. J Endocrinol Invest 38, 1025–1037 (2015). https://doi.org/10.1007/s40618-015-0274-y

Download citation

Keywords

  • PCOS
  • Reproduction
  • Infertility
  • Consensus statement
  • Guideline